Alterations in these biological pathways are hallmarks of several human diseases such diabetes, obesity, IBS/IBD, Crohn’s disease, atherosclerosis, gout, asthma, cardiovascular diseases, arthritis, hypertension, and colitis, therefore, targeting FFAR2/3 signaling can provide promising therapeutic strategies for these human diseases. This evidence concerns the gene FFAR2 and colitis.